Skip to main content

Table 1 Baseline characteristics

From: Macrocytosis may be associated with mortality in chronic hemodialysis patients: a prospective study

Variable

All

(n = 150)

MCV ≤ 102 fl

(n = 105)

MCV > 102 fl

(n = 45)

P

Demographic

    

   Age (years)

65.0 ± 17.0

63.3 ± 17.6

68.9 ± 15.1

0.07

   Time on dialysis (months)

34.5 ± 31.8

33.8 ± 34.4

36.4 ± 24.6

0.65

   Male n (%)

76 (51)

58 (55)

18 (40)

0.09

   Caucasian n (%)

135 (90)

91 (87)

44 (98)

0.04

   Fistula as HD access n (%)*

45 (30)

33 (31)

12 (27)

0.56

Cause of ESRD n (%)

    

   Diabetes

51 (34)

40 (38)

11 (24)

0.11

   Glomerulonephritis

29 (19)

18 (17)

11 (24)

0.30

Comorbidities n (%)

    

   Diabetes

63 (42)

45 (43)

18 (40)

0.75

   Hypertension

114 (76)

79 (75)

35 (78)

0.74

   Coronary artery disease

53 (35)

39 (37)

14 (31)

0.54

   Peripheral vascular disease

33 (22)

23 (22)

10 (22)

0.97

   Stroke

21 (14)

14 (13)

7 (16)

0.72

   Cancer

25 (17)

11 (10)

14 (31)

< 0.01

   Failed renal transplant

25 (17)

20 (19)

5 (11)

0.24

   Charlson-Age Comorbidity Index

7 ± 3

6 ± 3

8 ± 3

0.01

Laboratory

    

   Mean MCV (fl)

99.1 ± 6.4

96.0 ± 4.6

106.3 ± 3.1

< 0.01

   Albumin (g/L)

33.7 ± 3.5

34.0 ± 3.6

33.0 ± 3.3

0.14

   Hemoglobin (Hb) (g/L)

108.6 ± 10.0

109.8 ± 10.0

105.7 ± 9.6

0.02

   Hb btw. 100-120 g/L n (%)

103 (69)

73 (70)

30 (67)

0.65

   Ferritin ug/L

729 ± 467

707 ± 454

782 ± 498

0.37

   Tsat (%)

29.77 ± 11.80

28.05 ± 11.37

33.76 ± 11.93

< 0.01

   Darbepoetin alfa to Hb ratio

5.37 ± 3.66

4.80 ± 3.49

6.69 ± 3.73

< 0.01

Medications

    

   Darbepoetin alfa dose mcg/week

43.0 ± 31.5

39.3 ± 31.1

51.6 ± 31.1

0.03

   Receiving darbepoetin alfa n (%)+

141 (94)

97 (92)

44 (98)

0.27

   Receiving intravenous iron n (%)+

137 (91)

96 (91)

41 (91)

0.95

   Antiepileptic n (%)

5 (3)

1 (1)

4 (9)

0.01

   On folate n (%)

148 (99)

103 (98)

45 (100)

0.81

   On multivitamin

143 (95)

101 (96)

42 (93)

0.26

  1. *Patients without a fistula were dialyzed using a tunnelled, cuffed catheter, except for one using an AV graft
  2. +Received at least one dose during initial three months of study
  3. Continuous variables are reported as means ± standard deviation